Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot lung risk in brain injury patients

NCT ID NCT07664358

Diagnosis Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study looks at whether a simple blood test, called the fibrinogen-to-albumin ratio, can predict if someone with a traumatic brain injury will develop acute respiratory distress syndrome (ARDS), a serious lung condition. Researchers will measure these proteins in the blood of 350 adults admitted to the ICU within 24 hours of injury. The goal is to see if this ratio can help doctors identify high-risk patients early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could give doctors a simple blood test to identify TBI patients at high risk of ARDS, allowing earlier monitoring and treatment.
What could go wrong
This is an observational study, not a treatment trial. The test may not prove accurate enough for routine use, and results may not apply to all hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged ≥ 18 years admitted to the ICU within 24 hours of traumatic Brain Injury.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥ 18 years admitted to the ICU with traumatic Brain Injury * Admission to the ICU within 24 hours of injury. * Patients will be expected to remain under hospital care for follow-up * Availability of fibrinogen and albumin measurements within the first 24 hours of ICU admission. * Informed consent will be obtained from a legally authorized representative. Exclusion Criteria: * Preexisting advanced chronic liver disease, nephrotic syndrome, or protein-losing enteropathy. * Pre-existing ARDS on admission. * Recipient of albumin, fibrinogen concentrate, or cryoprecipitate before admission sampling. * Use of anticoagulant or fibrinolytic therapy before admission. * Active malignancy or severe systemic infection at admission. * Direct sever lung injury * Pregnancy * Refusal of consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Albumin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome Brain Injuries, Traumatic traumatic brain injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Albumin ARDS Fibrinogen Fibrinogen albumin ratio TBI (traumatic brain injury)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tanta University Hospitals

    RECRUITING

    Tanta, Gharbia Governorate, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.